# New Opportunities Arise as Cannabis is Legalized in Canada > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-legalization-in-canada-new-opportunities/ > **Published:** 2020-04-14T12:44:39-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:17:34-04:00 > **Clinical Summary:** Explore cannabis legalization in Canada and the new research opportunities it creates for health benefits and therapies. --- **“Tea” Time? [Cannabis Legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) in Canada** In Summary Last summer an op-ed came out in response to [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) in Canada discussing the risks and benefits of the legalization. The author acknowledges the myriad of health benefits that cannabis has been shown to treat but also brings forth the gaps in our knowledge that still remain. The piece urges physicians to fully discuss the most current information with their patients when recommending cannabis and for at-home cultivators to carefully manage their plants to prevent underage consumption. The author ends the piece on a hopeful note, mentioning that the only certainty of legalization cannabis is that much more robust research will be able to be conducted and provide more information for the public. The author emphasizes the research opportunities that have now opened up in Canada due to the legalization of cannabis, highlighting the limitations of [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) in the United States. As cannabis is currently ruled a schedule I drug under the Controlled Substances Act the federal government sees no medical benefit in [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/), despite an abundance of research. Researchers around the world have found evidence that cannabinoids, terpenes, and flavonoids can provide novel therapies for various disorders yet research in the US is still extremely limited by the lack of federal funding. Canada’s decision to legalize cannabis opens the door for so many [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) to be developed, and for economic and healthcare reasons, other countries should follow along. The study is available for review or download here: [DOWNLOAD & REVIEW HERE](https://www.cedfoundation.com/wp-content/uploads/2020/03/%E2%80%9CTea%E2%80%9D-time-Cannabis-legalization-in-Canada.pdf) View more studies like this in the CED Foundation Archive: [http://bit.ly/drcaplan](https://bit.ly/drcaplan) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators](https://cedclinic.com/cannabinoid-research-barriers-us-cannabis-market/) Explore the challenges faced by global cannabis operators due to differing regulations between the U.S. and Canada. [Read More](https://cedclinic.com/cannabinoid-research-barriers-us-cannabis-market/) [Cannabis use, anxiety and depression are all on the rise in Canada: study – CTV News](https://cedclinic.com/cannabis-use-mental-health-risks-canada-study/) A study highlighting the rising trends of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) alongside anxiety and depression in Canada. [Learn More](https://cedclinic.com/cannabis-use-mental-health-risks-canada-study/) [Cannabinoid Clinical Trials: Mental Health Evidence Review](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/) Review clinical trial evidence on cannabinoids and their impact on mental health conditions. [Explore Research](https://cedclinic.com/cannabinoid-clinical-trials-mental-health-evidence-review/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=New%20Opportunities%20Arise%20as%20Cannabis%20is%20Legalized%20in%20Canada&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-legalization-in-canada-new-opportunities%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-legalization-in-canada-new-opportunities%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=New%20Opportunities%20Arise%20as%20Cannabis%20is%20Legalized%20in%20Canada%20https%3A%2F%2Fcedclinic.com%2Fcannabis-legalization-in-canada-new-opportunities%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).